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Atherosclerosis, C-Reactive Protein, and Risk for
Open-Angle Glaucoma: The Rotterdam Study
Simone de Voogd,1 Roger C. W. Wolfs,2 Nomdo M. Jansonius,3 Jacqueline C. M. Witteman,1
Albert Hofman,1 and Paulus T. V. M. de Jong1,4,5
PURPOSE. To test the hypotheses that atherosclerosis and ele-
vated serum C-reactive protein (CRP) levels are risk factors for
open-angle glaucoma (OAG).
METHODS. In a prospective, population-based cohort study, all
participants 55 years and older and at risk for incident OAG
underwent, at baseline (1990–1993) and at follow-up (1997–
1999), the same ophthalmic examination, including visual field
testing and optic disc photography. Baseline atherosclerosis
was assessed by means of echography of the carotid arteries,
abdominal x-ray examination, and ankle–arm index; baseline
serum CRP levels were used in the analyses. The diagnosis of
OAG was based on an algorithm using optic disc measures and
visual field loss. Odds ratios of OAG were computed with
logistic regression analyses. Risk factors were categorized in
tertiles and according to standard deviation.
RESULTS. After a mean follow-up of 6.5 years, incident OAG was
diagnosed in 87 of 3842 (2.3%) participants at risk for OAG.
Carotid artery plaques, carotid intima–media thickness, aortic
calcifications, ankle–arm index, and CRP levels were not sig-
nificant risk factors for OAG. The odds ratio, given for the
highest and lowest tertiles, for carotid plaques was 1.43 (95%
confidence interval [CI], 0.68–2.99), for carotid intima–media
thickness 0.86 (95% CI, 0.47–1.57), for aortic calcifications
1.02 (95% CI, 0.60–1.75), for ankle–arm index 0.69 (95% CI,
0.38–1.25), and for CRP 1.19 (95% CI, 0.68–2.07).
CONCLUSIONS. In this prospective, population-based study, nei-
ther atherosclerosis nor serum CRP level was an important risk
factor for OAG. (Invest Ophthalmol Vis Sci. 2006;47:
3772–3776) DOI:10.1167/iovs.05-1278
Open-angle glaucoma (OAG) may be characterized as aretinal ganglion cell disorder leading to loss of nerve
fibers and cupping of the optic disc, so-called glaucomatous
optic neuropathy (GON), resulting in glaucomatous visual field
loss (GVFL).1,2 It is a progressive, blinding disease that has
substantial impact on daily functioning. Because of aging pop-
ulations, the burden of OAG on societies will increase.3 The
etiology of this process is still to be elucidated. One of many
theories is impaired perfusion of the optic disc, possibly
caused by autonomous vessel dysfunction or atherosclerosis.
Atherosclerosis is a systemic disease affecting arteries of all
sizes, including small ocular ones.4,5 Through thickening of the
intima and development of plaques, the vessel lumen de-
creases, eventually leading to disturbed perfusion and isch-
emia.6
Noninvasive ways to measure atherosclerosis include
echography of the carotid arteries for determining the intima–
media thickness or the presence of plaques,7 abdominal x-rays
for quantifying the amount of calcification in the aorta,8 and
ankle–arm index.9
Inflammation appears to play a role in the process of ath-
erosclerosis. Serum C-reactive protein (CRP), a general marker
of inflammation, has been associated with the occurrence of
atherosclerosis,10,11 and CRP level gives an indication of its
severity.12 Whether CRP is only a proxy or is causally related to
atherosclerosis has not been fully elucidated.10,11,13 Limited
information on the role of inflammatory factors as a cause for
primary OAG is available in small case-control studies.14,15 No
population-based studies have looked into atherosclerosis or
serum CRP as a risk factor for OAG, which is why we investi-
gated whether atherosclerosis or inflammation is a risk factor
for OAG in a general elderly white population.
METHODS
Study Population
The ophthalmic part of the Rotterdam Study, a prospective, popula-
tion-based cohort study of residents 55 years and older living in a
district of Rotterdam, has been described.16,17 In short, home inter-
views and examinations at the examination center were conducted
after the appropriate medical ethics committees had approved the
study protocol and all participants had given written informed consent,
according to the Declaration of Helsinki. After the baseline examina-
tion, from 1990 through 1993, a follow-up examination to study inci-
dent OAG was performed from 1997 through 1999.18
Measures of Atherosclerosis and CRP
Intima–media thickness was ultrasonographically determined in both
common carotid arteries, as was the presence of atherosclerotic
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plaques in these and in the internal carotid arteries and bifurcations
with the use of a 7.5-MHz linear-array transducer and a duplex scanner
(ATL UltraMark IV; Advanced Technology Laboratories, Bethel, WA).7
We computed a weighted plaque score (range, 0–6) by adding the
number of sites at which a plaque was detected, dividing by the total
number of sites for which an ultrasonographic image was available,
and multiplying by 6 (the maximum number of sites).19 Maximum
common carotid intima–media thickness was measured over a length
of 10 mm, with the beginning of the dilatation of the distal common
carotid artery as the reference point. We calculated the average of near-
and far-wall measurements and of left and right common carotid
arteries.7
We diagnosed abdominal atherosclerosis by radiographic detection
of calcified deposits in the aorta on a lateral abdominal film.8 The
extent of aortic calcification was classified according to the length of
the involved area (0 cm, 1.0 cm, 1.1–2.4 cm, 2.5–4.9 cm, 5.0–9.9,
and 10 cm, respectively). This resulted in scores from 0 to 5.20
Lower extremity atherosclerosis was expressed as the ankle–arm
index. Systolic blood pressure at the ankles (posterior tibial artery) was
measured in the supine position with a random-zero sphygmomanom-
eter and an 8-MHz continuous-wave Doppler probe (Huntleigh 500D;
Huntleigh Technology, Bedfordshire, UK). The ratio of systolic blood
pressure at the ankle and systolic blood pressure at the arm was the
ankle–arm index. The lowest index of both sides was used in the
analyses.9 Because arterial rigidity prevents arterial compression and
therefore may lead to spuriously high values of the ankle–arm index, an
index greater than 1.50 was considered invalid.21
Nonfasting blood was collected at baseline, and all tubes were
stored on ice before and after blood sampling. High-sensitivity CRP was
determined in serum, which was stored at –20°C until performance of
the CRP measurements in 2003 and 2004. We measured CRP using a
rate near infrared particle immunoassay (Immage Immunochemistry
System; Beckman Coulter, Fullerton, CA). Outliers (values 3 SD
distribution) of logarithmically transformed CRP were excluded be-
cause they might indicate the presence of active inflammatory disease.
Assessment of Open-Angle Glaucoma
The procedure for assessing OAG has been described.16,17 In short,
ophthalmic examination included Goldmann applanation tonometry,22
visual field screening, ophthalmoscopy, and stereoscopic fundus pho-
tography in pharmacologic mydriasis, with similar procedures at base-
line and follow-up.18,23
For GON evaluation, simultaneous stereocolor transparencies were
digitized and analyzed with a semiautomated image analyzer. If the
transparencies were absent or of bad quality, ophthalmoscopic esti-
mates were used. Possible GON was defined as vertical cup-to-disc
ratio 0.7 or asymmetry between eyes of 0.2 or minimal rim width
0.1 and probable GON as vertical cup-to-disc ratio 0.8 or asymme-
try between eyes of 0.3 or minimal rim width 0.05, based on the
97.5 and 99.5 percentiles in this population.16 Visual fields were
screened with automated suprathreshold perimetry. A defect in either
eye, defined as nonresponse to a light stimulus in at least three con-
tiguous tests points or in four contiguous test points when the blind
spot was included, was checked by Goldmann perimetry on both
eyes.23 Visual field loss, compatible with OAG (thus excluding hemi-
anopia, quadrantanopia, or isolated central defect) and not explained
by other (neuro-) ophthalmic causes was defined as GVFL.17,23
The diagnosis OAG was based on an algorithm using GON and
GVFL, independent of intraocular pressure, and could only be made in
participants who had—in at least one and the same eye—an open
anterior chamber angle and no history or sign of angle-closure or
secondary glaucoma.16,18 Definite OAG was defined as the presence of
possible or probable GON and GVFL; probable OAG as probable GON
without GVFL, or GVFL without GON. Possible OAG referred to
possible GON only.16 Incident OAG was defined as no or possible OAG
in either eye at baseline and as probable or definite OAG in at least one
eye at follow-up.18 Excluded from this incidence definition were par-
ticipants with possible GON at baseline and probable GON at fol-
low-up as the only change, because a tiny increase in one of the GON
criteria could lead to a change in this classification. We used this
exclusion criterion primarily because we wanted to be as confident as
possible that we really used cases with incident OAG in the risk
analyses. We preferred to speak of OAG instead of primary OAG
because at baseline we did not specifically exclude pseudoexfoliation
glaucoma in all participants. This, however, was never encountered
during subsequent examinations at baseline or follow-up.
Population for Analysis and Data Analysis
At baseline, 6780 participants (78% of those eligible) underwent oph-
thalmologic examination. After excluding persons with prevalent def-
inite or probable OAG (n  221) and those without data on perimetry
and optic disc measures (n  7), 6552 participants formed the cohort
at risk for incident OAG.
Data on carotid plaques were available in 5385 persons, carotid
intima–media thickness in 5417, aortic atherosclerosis in 5520, periph-
eral atherosclerosis in 5890, and serum CRP levels in 6111. Thirty-four
participants were excluded because of ankle–arm index greater than
1.50, and 27 were excluded as CRP outliers.
We used univariate analyses of covariance to compare baseline
characteristics of participants and nonparticipants in the follow-up
examination, with appropriate adjustment for age and sex. Serum CRP
was log transformed in the analyses with standard deviations because
its distribution was skewed. Logistic regression analyses were used to
calculate odds ratios with corresponding 95% CIs, which can be inter-
preted as relative risks. In further analyses we adjusted for age, sex, and
follow-up time. Carotid intima–media thickness, ankle–arm index, and
CRP were analyzed in tertiles and according to standard deviation.
Carotid plaques and aortic calcifications were categorized in three
groups and analyzed according to these groups or according to cate-
gory increase. All analyses were performed with current software (SPSS
for Windows, version 11; SPSS Inc., Chicago, IL).
RESULTS
After a mean follow-up time of 6.5 years (range, 5.0–9.4 years),
1244 participants had died and 1466 declined or were unable
to participate in the follow-up examination of the cohort at risk
for incident OAG, leaving 3842 persons (participation rate,
72%). Baseline characteristics of the cohort at risk are provided
in Table 1. Most variables were significantly different between
participants and those who refused or died. This was not true
of the OAG-related variables.
Incident OAG was diagnosed in 87 persons. Table 2 shows
that baseline atherosclerosis—analyzed in tertiles, groups, and
per SD or category—was not associated with incident OAG.
There seemed to be a trend toward higher OAG incidence with
increasing numbers of carotid plaques, but the 95% confidence
intervals were too wide to draw a more definite conclusion.
Table 3 shows that elevated baseline serum CRP levels,
analyzed in tertiles and per SD, also constituted no risk for
incident OAG.
We also analyzed incident OAG in those persons excluded
for extreme CRP levels. At follow-up, 15 of the 27 persons
were dead, four refused to participate, and eight participated
in the follow-up examinations. No incident OAG was seen in
these eight participants.
To look for bias from dropout, we calculated the preva-
lences of probable or definite OAG at baseline in persons
who at follow-up had died, refused to participate, or partic-
ipated. Adjusted for age and sex, no differences were ob-
served between those who died (3.7%), refused (3.4%), or
participated (3.1%).
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Age, y 65.7  6.9 71.2  8.7†† 77.4  9.1††
Female, % 57.8 68.6†† 54.3††
Vertical cup-disc ratio‡ 0.53  0.13 0.50  0.15†† 0.48  0.17††
Possible open-angle glaucoma, % 7.9 7.2 7.6
Intraocular pressure, mm Hg§ 15.1  3.1 15.2  3.4 14.8  3.4
Intraocular pressure treatment, % 1.8 2.7 2.3
Body mass index, kg/m2 26.3  3.5 26.7  4.0†† 25.8  3.9††
Diabetes mellitus, % 6.9 10.6†† 20.9††
Systemic hypertension, % 28.9 38.4†† 45.5††
Total cholesterol, mmol/L 6.7  1.2 6.7  1.2 6.3  1.3††
HDL cholesterol, mmol/L 1.4  0.4 1.4  0.4 1.3  0.4††
History of stroke, % 1.3 3.5†† 7.2††
Demented, % 0.2 3.4 15.2††
Intima–media thickness, mm 0.77  0.14 0.81  0.16†† 0.89  0.18††
Carotid plaques score¶ 1.28  1.56 1.68  1.72†† 2.40  1.90††
Aortic calcification score# 1.47  1.39 1.93  1.48†† 2.32  1.48††
Ankle–arm index 1.11  0.18 1.03  0.23†† 0.91  0.29††
C-reactive protein, mg/L** 1.57  2.65 1.90  2.62†† 2.74  3.03††
Data are unadjusted mean  SD for continuous variables and percentages for dichotomous variables.
* Unable or refused at follow-up.
† Persons who died before the follow-up examination.
‡ Measured as maximum vertical cup-to-disc ratio of both eyes.
§ Only presented here for persons without IOP-lowering treatment. Measured as maximum intraoc-
ular pressure in either eye.
¶ Score ranges from 0 through 6.
# Score ranges from 0 through 5.
** Based on mean from the natural logarithm (back-transformed).
†† Significant (P  0.05) compared with participants, after adjusting for age and sex if applicable.




at Risk OAG Cases
Relative Risk
(95% CI)* (95% CI)†
Carotid plaques
Low 1525 25 1.00 — 1.00 —
Intermediate 1315 38 1.79 (1.07–2.97) 1.55 (0.92–2.61)
High 389 11 1.75 (0.85–3.58) 1.43 (0.68–2.99)
Per category increase 3229 74 1.40 (1.02–1.93) 1.26 (0.90–1.75)
Carotid intima–media thickness
Low 1080 23 1.00 — 1.00 —
Intermediate 1085 24 1.04 (0.58–1.85) 0.84 (0.47–1.53)
High 1082 29 1.27 (0.73–2.20) 0.86 (0.47–1.57)
Per SD increase 3247 76 1.11 (0.89–1.38) 0.95 (0.75–1.22)
Aortic calcification
Low 1358 32 1.00 — 1.00 —
Intermediate 1263 23 0.77 (0.45–1.32) 0.63 (0.36–1.09)
High 874 29 1.42 (0.85–2.37) 1.02 (0.60–1.75)
Per category increase 3495 84 1.18 (0.90–1.55) 1.01 (0.75–1.34)
Ankle–arm index
Low 1172 21 0.77 (0.43–1.37) 0.69 (0.38–1.25)
Intermediate 1171 27 1.00 (0.58–1.72) 0.98 (0.57–1.70)
High 1174 27 1.00 — 1.00 —
Per SD decrease 3517 75 0.90 (0.71–1.15) 0.86 (0.67–1.09)
Ranges (low, intermediate, high): carotid plaque score: 0, 1–3, 4–6; carotid intima–media thickness:
0.41–0.70, 0.70–0.81, 0.81–1.71; aortic calcification score: 0, 1–2, 3–5; ankle–arm index: 0–1.06, 1.06–
1.19, 1.19–1.50.
* Unadjusted model.
† Adjusted for age, sex, and follow-up time.
3774 de Voogd et al. IOVS, September 2006, Vol. 47, No. 9
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933235/ on 05/03/2018
DISCUSSION
In our study we could not find an association between athero-
sclerosis or serum CRP levels at baseline and incident OAG.
Impaired perfusion of the optic disc caused by atherosclerosis or
inflammation is therefore not likely to be a major cause of OAG.
Earlier studies have measured atherosclerosis through
echography or x-ray of the carotid arteries in clinic-based case
series or within specific patients groups, such as those with
low-tension OAG, high-tension OAG, or ocular hypertension
or in healthy controls.24 –31 Despite some positive findings,
no strong association could be found.32–35 Another theory
states that vascular dysregulation rather than chronically
reduced blood flow by atherosclerosis may lead to local
vasospasm and to systemic hypotension, which can lead to
low perfusion pressure and insufficient autoregulation of the
blood supply of the optic nerve head.5,33,35–38 Similarly,
vascular dysregulation of other areas, such as the brain and
the cardiovascular system, have been described in glaucoma
patients.39,40
The role of inflammation as a risk factor for primary OAG is
not as clear as it is for secondary glaucoma. In secondary
glaucoma, inflammatory proteins and cells may cause mechan-
ical blockage or damage to the trabeculum, leading to in-
creased intraocular pressure.41 In what way could inflamma-
tion cause primary OAG? During inflammation, several acute-
phase proteins are released, including CRP. In recent years it
has become clear that CRP may be not only a biomarker but an
active mediator in the pathogenesis of atherosclerosis. Athero-
sclerosis begins as a response to insults to the endothelium and
smooth muscle cells of the arterial wall, and this process is
accompanied by inflammatory processes in which CRP can
take an early and active part. This can lead to impairment of the
circulation with accompanying hypoperfusion or even nonper-
fusion of tissues. In this study, we could not demonstrate that
this pathway works for OAG as it does for cardiovascular
diseases.
In an old study,14 no elevated serum CRP level was seen in
eight OAG patients. A more recent case-control study found
higher CRP levels in patients with normal-tension glaucoma
than in healthy controls.15 In separate analyses on incident
normal-tension and incident high-tension glaucoma, we found
no difference from the combined results presented in Table 3.
Possible explanations are the differences in study design (cross-
sectional vs. longitudinal), in population characteristics (CRP
level in their controls15 was lower than in our population), in
laboratory assays, and in OAG definition.
Another optic nerve disease may show cupping similar to
that seen in OAG. This is arteritic anterior ischemic optic
neuropathy induced by giant cell arteritis.42 In giant cell arteri-
tis, the vessel walls become infiltrated with monocytes and
macrophages, leading to intimal thickening. This can result in
complications, such as permanent occlusion of posterior cili-
ary arteries with ischemia of the optic nerve head. The patho-
physiology of optic disc cupping in arteritic anterior ischemic
optic neuropathy, however, seems to be different from that in
OAG because the former is usually associated with highly
elevated levels of CRP and other acute-phase proteins,43 shows
profound disc pallor after a period of disc edema, and has a
shorter time course.
We looked into the possible pathways of atherosclerosis
and CRP for OAG. In spite of our large cohort, we had a limited
number of incident OAG cases partially because of the pro-
spective, population-based design. By using strict and, as much
as possible, objective criteria to diagnose incident OAG, we
tried to eliminate misclassification. Some incident OAG cases
might have been missed because of these strict definitions.
For risk analysis we considered it better to transfer a possi-
ble case into the large control group than to contaminate the
case group with healthy persons. Our criteria led to high
specificity but relatively low sensitivity. This underestima-
tion of the cases was independent of CRP or atherosclerosis
status; therefore, relative risk was unaffected. The limited
number of cases did affect the precision of our estimates. Had
we had more OAG cases, we still estimate that any effect of
atherosclerosis or CRP on the incidence of OAG would have
remained small.
A potential limitation of our study was the relatively large
group of persons who were lost to follow-up. This can partially
be explained by the number of deaths that occurred during
follow-up in this elderly cohort. However, two studies show
that patients with OAG are not at increased risk for death,
making survival bias as an explanation for our negative findings
less likely.44,45 Furthermore, participants who refused the fol-
low-up examination differed in several aspects, including ath-
erosclerosis measures and CRP levels, compared with those
who participated at follow-up. We have no reason to believe
that the relation between CRP and OAG will be different
among those who left the study and those who remained in the
study. However, our risk estimates may be underestimated
because the range of CRP levels in the upper tertile will be
more limited in our study. Given that the risk estimate for this
tertile was close to 1, we do not believe that an important
effect of CRP on OAG, if present, was missed in our study. The
age difference between participants and nonparticipants might
have resulted in fewer incident cases, leading to larger confi-
dence intervals in this study, because the incidence of OAG
rises with age.18
All measures of atherosclerosis in this study reflected the
amount of generalized atherosclerosis. They function as a
proxy for atherosclerosis in the vessels and are important for
OAG. We assumed there would be no difference between
TABLE 3. Relative Risks of Incident Open-Angle Glaucoma according to Baseline Serum C-Reactive





(95% CI)* (95% CI)†
Low 1205 23 1.00 1.00
Intermediate 1205 33 1.45 (0.85–2.48) 1.40 (0.81–2.40)
High 1208 29 1.26 (0.73–2.20) 1.19 (0.68–2.07)
Per SD increase 3618 85 1.10 (0.88–1.38) 1.06 (0.85–1.34)
Ranges, C-reactive protein (low, intermediate, high): 0.20–1.03, 1.04–2.46, 2.47–41.0.
* Unadjusted model.
† Adjusted for age, sex, and follow-up time.
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generalized and localized atherosclerosis, but this also re-
quires further exploration. In summary, we were unable to
detect a significant association between atherosclerosis or
serum CRP level and incident OAG in a relatively healthy
population.
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